This announcement is an advertisement and not a prospectus. Neither this announcement nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Investors should not purchase any transferable securities referred to in this announcement except on the basis of information contained in the prospectus (the Prospectus ) in its final form that is published by Tiziana Life Sciences plc in connection with the admission of the Company s ordinary shares (the Ordinary Shares ) to listing on the standard segment of the Official List of the Financial Conduct Authority (the FCA ) and to trading on the main market for listed securities (the Main Market ) of London Stock Exchange plc (the London Stock Exchange ). This announcement is not an offer to sell, or a solicitation of an offer to acquire, securities in the United States, Australia, Canada, Japan or in any other jurisdiction.
Tiziana or the
Company ), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces it has applied to list its ordinary shares ( Ordinary Shares ) on the standard listing segment of the Official List of the Financial Conduct Authority ( FCA ) (the Official List ) and admission to trading on the London Stock Exchange plc s (the London Stock Exchange ) main market ( Main Market ) for listed securities (together, Admission ). The Board has taken this decision as it believes that a standard listing will afford Tiziana greater flexibility in pursuing its strategy as an international company.
Pursuant to AIM Rule 41 of the AIM Rules for Companies, the Company hereby gives notice of the intended cancellation of trading of its Ordinary Shares on the AIM market of the London Stock Exchange ( AIM ).
London, New York, 17 December 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ( Tiziana or the Company ), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces it has applied to list its ordinary shares ( Ordinary Shares ) on the standard listing segment of the Official List of the Financial Conduct Authority ( FCA ) (the Official List ) and admission to trading on the London Stock Exchange plc s (the London Stock Exchange ) main market ( Main Market ) for listed securities (together, Admission ). The Board has taken this decision as it believes that a standard listing will afford Tiziana greater flexibility in pursuing its strategy as an international company.